FDA Adverse Event Other Summary report: N

BLU-U BLUE LIGHT PHOTODYNAMIC THERAPY ILLUMINATOR

MDR report key: 3807966 · Received May 9, 2014

Report

Report Number
1226354-2014-00002
Event Type
Other
Date Received
May 9, 2014
Date of Event
April 14, 2014
Report Date
May 8, 2014
Manufacturer
DUSA PHARMACEUTICALS, INC.
Product Code
MVF
PMA / PMN Number
P990019
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
TX, US
Reporter Occupation
PHYSICIAN

Narratives

Description of Event or Problem · 1

A (B)(6) FEMALE PATIENT RECEIVED TREATMENT FOR ACTINIC KERATOSES WITH LEVULAN KERASTICK AND BLU-U BLUE LIGHT PHOTODYNAMIC THERAPY ILLUMINATOR CONSISTING OF A SKIN PREPARATION WITH CERAVE CLEANSER AND WATER, FOLLOWED BY APPLICATION OF LEVULAN KERASTICK TO THE ENTIRE FACE, INCUBATION OF 1 HOUR, FOLLOWED BY 16 MINUTES 40 SECONDS OF EXPOSURE TO BLU-U LIGHT. PATIENT HAS A HISTORY OF MELANOMA AND ACTINIC KERATOSES AND IS ON WELLBUTRIN FOR ANXIETY AND DEPRESSION. TWO DAYS POST TREATMENT THE PATIENT REPORTED TO HER PHYSICIAN THAT SHE HAD BLISTERS, ITCHING AND SKIN TIGHTNESS. THE PHYSICIAN TOLD HER TO APPLY SPECIFIC TOPICALS FOR RELIEF. THE PATIENT REPORTED THE FOLLOWING MONDAY (3 DAYS AFTER LEVULAN/BLU-U TREATMENT (B)(6) 2014) THAT THE BLISTERS HAD RESOLVED, BUT HER SKIN WAS STILL TIGHT TO WHICH THE PHYSICIAN SUGGESTED VASELINE/DOMEBORO SOAKS. THAT NIGHT ((B)(6) 2014) THE PATIENT REPORTED SHE HAD A SEIZURE. EMS WAS CALLED WHO EVALUATED THE PATIENT BUT DID NOT TRANSPORT HER TO THE HOSPITAL. LATER THAN EVENING THE PATIENT REPORTED HAVING ANOTHER SEIZURE/EVENT AND WAS TAKEN TO THE EMERGENCY ROOM. THE PATIENT'S DERMATOLOGIST REPORTED THAT THE EMERGENCY ROOM PHYSICIAN STATED THE WELLBUTRIN CAUSE THE SEIZURE ACTIVITY. IT IS THE OPINION OF THE COMPANY'S CHIEF MEDICAL OFFICER THAT THE WELLBUTRIN CAUSED THE SEIZURE AND THE EVENT WAS NOT RELATED TO THE LEVULAN KERASTICK/BLU-U TREATMENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
282097 BLU-U BLUE LIGHT PHOTODYNAMIC THERAPY ILLUMINATOR BLU-U MVF DUSA PHARMACEUTICALS, INC. BLU-U 10K NA

Patients

Seq Age Sex Outcome Treatment
1 44 YR Other